anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a fusion protein, the amino acid sequence of which contains an iRGD peptide sequence shown as SEQ ID No:1 and a molecular chaperone GroEL sequence shown as SEQ ID No:2. The invention further discloses an encoding gene of the fusion protein, the sequence of which is a nucleotide sequence capable of encoding the fusion protein. The invention further discloses a preparation method of the fusion protein. The preparation method comprises the following step of expressing the encoding gene in a bacterial strain to obtain the fusion protein. A method of preparing a pharmaceutical composition comprises the following steps of contacting the pharmaceutical compound with the fusion protein disclosed by the invention to obtain a contacted material in the presence of a solvent. The invention further discloses the pharmaceutical composition prepared by the method of preparing the pharmaceutical composition. The fusion protein provided by the invention can stably load a hydrophobic drug, and is high in drug-carrying efficiency and good in drug release effect. The pharmaceutical composition prepared by the fusion protein provided by the invention has the advantages of good biocompatibility and good drug release effect.
Patients receive ifosfamide, carboplatin and etoposide as in Arm A. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Autoinhibition is a prevalent allosteric regulatory mechanism in signaling proteins. Reduced autoinhibition underlies the tumorigenic effect of some known cancer drivers, but whether autoinhibition is altered generally in cancer remains elusive. Here, we demonstrate that cancer-associated missense mutations, in-frame insertions/deletions, and fusion breakpoints are enriched within inhibitory allosteric switches (IASs) across all cancer types. Selection for IASs that are recurrently mutated in cancers identifies established and unknown cancer drivers. Recurrent missense mutations in IASs of these drivers are associated with distinct, cancer-specific changes in molecular signaling. For the specific case of PPP3CA, the catalytic subunit of calcineurin, we provide insights into the molecular mechanisms of altered autoinhibition by cancer mutations using biomolecular simulations, and demonstrate that such mutations are associated with transcriptome changes consistent with increased calcineurin signaling. Our integrative study shows that autoinhibition-modulating genetic alterations are positively selected for by cancer cells.
1. Use of 5-(2-ethyl-2H-tetrazol-5-yl)-1,2,3,6-tetrahydro-l-methylpyridine   or a pharmaceutically acceptable salt thereof as an active substance for the manufacture of a pharmaceutical preparation for the treatment of traumatic brain injury. 2. Use according to Claim 1, characterized in that in said pharmaceutical preparation said active substance is used in a unit dosed form. 3. Use according to any of Claims 1-3, characterized in that the pharmaceutical preparation manufactured is for the treatment of traumatic brain injury caused by physical forces acting on the scull or spinal column, ischaemia, stroke, arrested breathing, cardiac arrest, cerebral thrombosis or emboism, neurological problem caused by AIDS, cerebral hemorrhage, encephalomyelitis, hydrocephalus, post-operative events, cerebral infections, concussions or elevated intracranial pressure and or for the treatment of the sequelae of such a condition.
BACKGROUND: Operating room to intensive care unit handoffs are high-risk events for critically ill patients. Studies in selected patient populations show that standardizing operating room to intensive care unit handoffs improves information exchange and decreases errors. To adapt these findings to mixed surgical populations, the investigators propose to study the implementation of a standardized operating room to intensive care unit handoff process in two intensive care units currently without an existing standard process. METHODS/DESIGN: The Handoffs and Transitions in Critical Care (HATRICC) study is a hybrid effectiveness-implementation trial of operating room to intensive care unit handoffs. The investigators will use mixed methods to conduct a needs assessment of the current handoff process, adapt published handoff processes, and implement a new standardized handoff process in two academic intensive care units. Needs assessment - The investigators will use nonparticipant observation to observe the current handoff process. Focus groups, interviews, and surveys of clinicians will elicit participants' impressions about the current process. Adaptation and implementation - The investigators will adapt published standardized handoff processes using the needs assessment findings. The investigators will use small group simulation to test the new process' feasibility. After simulation, the investigators will incorporate the new handoff process into the clinical work of all providers in the study units. Evaluation - Using the same methods employed in the needs assessment phase, the investigators will evaluate use of the new handoff process. Data analysis - The primary effectiveness outcome is the number of information omissions per handoff episode as compared to the pre-intervention period. Additional intervention outcomes include patient intensive care unit length of stay and intensive care unit mortality. The primary implementation outcome is acceptability of the new process. Additional implementation outcomes include feasibility, fidelity and sustainability. DISCUSSION: The HATRICC study will examine the effectiveness and implementation of a standardized operating room to intensive care unit handoff process. Findings from this study have the potential to improve healthcare communication and outcomes for critically ill patients.
This group will receive standard kinetic programs consisting of stretching (2 sets 15 repetitions with 5 seconds hold) , passive mobilizations (2 sets of 20 repetitions), orthosis( for 6 hours). These techniques and orthotics devices typically focus on tight muscles, maintain proper foot alignment and to address sensory processing difficulties and promote relaxation. Stretching will focus on the hamstrings and calf muscles tightness.
The slow released compound anticancer injection with angiogenesis inhibitor and bendamustine consists of slow released microsphere and solvent. The slow released microsphere includes effective anticancer component and slow releasing supplementary material, and the solvent is special solvent containing suspending agent. The angiogenesis inhibitor is selected from fumagillin, geftinib, thalidomide, etc. The slow releasing supplementary material is polifeprosan, polylactic acid and its copolymer, EVAc, etc. The .suspending agent is carboxymethyl cellulose sodium, etc. and has viscosity of 100-3000 cp at 20-30 deg.c. The slow released microsphere may be also prepared into slow released implanting agent. The present invention has lowered systemic reaction and raised local concentration, and may be used in inhibiting the growth of tumor cell and blood vessel and in enhancing the curative effect of chemotherapy, radiotherapy and other non-operative treatment.
Autopsy of infants can provide vital information about the cause of death and contributes to the detection of diagnostic errors, especially in a low- or middle-income country. To observe the clinicopathological agreement in neonatal deaths in neonatal intensive care units (NICU) and comment on the additional information retrieved by autopsy. A retrospective observational study was conducted in the NICU from January 2020 to December 2022. Neonatal deaths were analyzed, and clinical details and autopsy findings were collected. Both clinical and pathological diagnoses were classified according to the Goldman classification. Twenty-two newborn infants were enrolled. The mean gestational age was 33.5 (±4.38) weeks, and the median birth weight was 1510 (1005-2100) g. There was complete concordance between clinical and pathological diagnosis in 11 (50%) cases. Major diagnostic errors occurred in 41% of cases. Respiratory system disorders (lung infections, airway anomalies) accounted for six (54%) cases of missed diagnosis. Our study showed that the diagnosis was revised after autopsy in about one-third of cases, and newer findings were identified in one-fifth of cases.
Control group: ASD children were asked to do memory training (i.e. 1 back) for eight weeks using iPAD. Two 15-minsute sessions each day was required.
Therapy will be performed bilaterally on the upper limbs. The ischemic conditioning group will perform 4 times, 8 cycles with 30 seconds of ischemia (80 - 200 mmHg) with 5 seconds of reperfusion in each cycle. Ischemia cycles are controlled by a device (KAATSU C3 - KAATSU GLOBAL / USA) In the first cycle, participants will be subjected to pressures of 80 to 150 mmHg. In the 3 subsequent cycles, pressures from 130 to 200 mmHg will be applied.
NEW MATERIAL:A compound shown by the formula (phi is phenyl; X and Y are phenyl or hydroxyl group). EXAMPLE:Diphenylphosphinyldifluoromethylphosphonic acid. USE:A dental remedy material, or a medical reinforcing material for bone. PROCESS:An organometallic compound containing diphenylphosphinyldifluoromethyl group is reacted with a trivalent phosphorus compound (e.g., trichlorophosphine, etc.), to give a compound shown by the formula I . An organozinc compound, a reaction product of bromofluoromethyldiphenylphosphine oxide and metal zinc, is preferably used as the organometallc compound containing diphenylphosphinylfluorodiphenyl methyl group.
MESNEX (mesna) is a detoxifying agent to inhibit the hemorrhagic cystitis induced by ifosfamide. The active ingredient, mesna, is a synthetic sulfhydryl compound designated as sodium-2-mercaptoethane sulfonate with a molecular formula of C2H5NaO3S2 and a molecular weight of 164.18. Its structural formula is as follows:

HS–CH2–CH2SO3–Na+

MESNEX injection is a sterile, nonpyrogenic, aqueous solution of clear and colorless appearance in clear glass multidose vials for intravenous administration. MESNEX injection contains 100 mg/mL mesna, 0.25 mg/mL edetate disodium and sodium hydroxide for pH adjustment. MESNEX injection multidose vials also contain 10.4 mg/mL of benzyl alcohol as a preservative. The solution has a pH range of 7.5-8.5.

MESNEX tablets are white, oblong, scored biconvex film-coated tablets with the imprint M4. They contain 400 mg mesna. The excipients are calcium phosphate, cornstarch, hydroxypropylmethylcellulose, lactose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, povidone, simethicone, and titanium dioxide.
We aimed to investigate the effects of dual- and single-task training in older adults with age-related hearing loss. Intervention groups included single-, dual-task training, and control groups. The dual- and single-task trainings were held 2 days a week for 40 min for a total of 10 sessions for 5 weeks. We evaluated physical, cognitive, and auditory functions, quality-of-life, balance, concerns about falling, independence in activities of daily living, and dual-task performance. A total of 42 patients fully participated in this study. Statistically significant differences were observed in chair stand, chair sit-and-reach, global cognitive function, and delayed recall between the intervention groups and control group (p < .05). There was no statistically significant difference in quality-of-life, balance, falling concerns, independence in activities of daily living, and dual-task performance between all groups (p > .05). In conclusion, single- and dual-task training had a positive effect on physical and cognitive functioning in older adults with age-related hearing loss.
Skin tightening compositions for application to the skin for providing an instantaneous and dramatic improvement to the appearance of skin. The skin tightening compositions typically include about 5 to about 45 wt. % or more of one or more hydrophobic film-forming polymers comprising acrylates/stearyl methacrylate copolymer; about 0.5 to about 20 wt. % of a mineral thickening agent; about 1 to about 15 wt. % of a silicone elastomer; and about 30 to about 85 wt. % of a volatile hydrocarbon oil, wherein all percentages by weight are based on the total weight of the skin tightening composition. Additionally, the skin tightening composition may have a weight ratio of the total amount of hydrophobic film-forming polymers to the total amount of mineral thickening agent is 1:1 to 10:1 and a weight ratio of the total amount of silicone elastomer to the total amount of mineral thickening agent is 1:2 to 8:1.
Central diabetes insipidus (CDI) typically manifests as a polyuria-polydipsia syndrome, in which normonatremia is generally maintained through the polydipsia. A 53-year-old woman presented with diabetic ketosis and hyperosmolar hyperglycemic syndrome. Her medical history included herpes meningoencephalitis, which was associated with confusion and amnesia. On physical examination, she was apyretic, confused, and had signs of extracellular dehydration. Her capillary glucose concentration was high and her urine was positive for ketones. Laboratory investigations revealed severe hyperglycemia, hypernatremia (plasma hyperosmolarity of 393.6 mOsm/L), and mild acute renal failure. In addition, she had a paucisymptomatic COVID-19 infection. Intravenous rehydration with isotonic saline solution and insulin therapy were effective at controlling the ketosis and ameliorating the hyperglycemia, but failed to normalize the hypernatremia and hyperosmolarity. She was not thirsty and had a urine output of 1 L/day, with urinary hypotonicity. Desmopressin administration reduced the hypernatremia and hyperosmolarity to within their normal ranges, and the patient's urinary osmolarity increased to 743 mOsm/L. Therefore, adipsic CDI was diagnosed. Endocrine investigations revealed isolated central hypothyroidism. The results of pituitary magnetic resonance imaging were normal. Thus, patients with impaired thirst may have an atypical presentation of CDI. In addition, the diagnosis of adipsic CDI is particularly challenging.
In this treatment protocol, patients will receive a total radiation dose of 24Gy in three fractions, specifically targeting the primary tumor. Concurrently, the axillary lymph nodes will be treated with a dose of 9Gy in three fractions. This radiation therapy will be conducted over a period of 3 to 5 working days. Following the radiation therapy, toripalimab will be administered between the second and fifth days after the completion of the radiation treatment. After a three-week interval, patients will proceed with the standard neoadjuvant chemotherapy regimen combined with toripalimab. This regimen includes an initial phase of four cycles of paclitaxel paired with toripalimab, which will be followed by a subsequent phase of four cycles of epirubicin paired with toripalimab.
The lidocaine group will be administered a 1,000 ml distention medium containing 5 ml lidocaine per 250 ml (DEBOCAINE (LIDOCAINE) 2% 1 VIAL 50 ML, Sigma-Tec pharmaceutical Industry. Co. Egypt) and oral placebo similar to tramadol(given 1 hour before the procedure).
This is a kind of medicine for treating infant cold. The medicine is prepared by using honeysuckle, forsythia suspensa Vahl, herba schizeneptae, mint, matricaria indica. Its preparing method is: firstly make the above raw materials into Chinese traditional medicinal decoction pieces, then add water to the honeysuckle, forsythia suspensa vahl, herba schizeneptae, mint, asket fern, dry flea, platycodon glaucus nak, matricaria indica of the above medicinal decoction pieces and extract their distilled oil, and let the left water standby. Mix the dregs of decoction with asket fern, dry flea, Platycodon glaucus Nak and add water, then distill and filter them, unite the filtered liquids and have them condensed, add ethanol into the condensed liquid and put them in the cold storage still, after that, filter and condense them again, add supplementary materials and the distilled oil to the condensed liquid. After all this, make the mixture into oral liquid or syrups, granule preparation, small pills, tablet (solvable or scattered tablets), capsuls(soft capsula) and so on. This invented medicine has the effective functions of anti-virus, anti-bacteria, fever relieving, killing pains, antiphlogosis. Clinical applications show It has obvious effectiveness in treating infant cold with the recovering efficiency of above 90%, without side effects.
1. A method of isomerisation, characterized in that a compound of formula (1A)   wherein X and Y together form either a 3-oxo radical or X is a hydrogen atom and Y is either a radical   where R2 is OH or O-acyl, comprising from 2 to 20 carbon atoms or NH2 radical, R1 is a hydrogen atom or methyl, Z is hydrogen or acyl, comprising from 2 to 20 carbon atoms, R is a hydrogen atom, NH2 radical or a (CH2)nAr or N=CH(CH2)nAr, where n is an integer from 1 to 6, and Ar is aryl or heteroaryl, which can be substituted, in the form of a 10α or a mixture of 10α and 10β isomers is exposed to a basic agent to give the corresponding compound of formula (I) in which the 10-methyl radical is in the β position   and in which R, R1 X and Y preserve their previous values and Z<1> is a hydrogen atom or acyl comprising from 2 to 20 carbon atoms. 2. The method of claim 1, characterized in that said method is carried out in the presence of the basic agent and Z and Z<1> are a hydrogen atom. 3. The method of claim 1 or 2, characterized in that the basic agent is potassium hydroxide. 4. The method of claim 1 or 2, characterized in that the basic agent is hydroxide or tetrabutylammonium bromide or an alkali carbonate, for example, sodium or potassium carbonate or potassium hydroxide or DBU (1,8-diazabicyclo [5-4] undec 7-ene) or tripotassium phosphate or sodium methylate. 5. The method of any preceding claim, characterized in that said method is carried out in a solvent which can betetrahydrofurane, 1-methyl-2-pirrolidinone in an aqueous solution, methylene chloride or alcohol to give the corresponding compound in which Z<1> is a hydrogen atom or acyl comprising from 2 to 20 carbon atoms. 6. The method of claim 5, characterized in that said method is carried out in methanolic solution. 7. The method of any preceding claim, characterized in that R is NH2 radical. 8. The method of any preceding claim, characterized in that R1 is methyl-9 9. The method of any preceding claim, characterized in that X and Y form together 3-oxo radical. 10. The method of any preceding claim, characterized in that Z and Z<1> are a hydrogen atom.
1311385 Artificial teeth Y SIMONPAOLI 19 April 1971 [10 Feb 1970 28 Jan 1971] 22168/71 Heading A5R An artificial denture is manufactured by providing a moulded metal core 10 provided with keying depressions 14 at its upper surface, degreasing the surface of the metal core, and then subjecting the core to thermal degassing treatment, coating the upper surface of the core with a bonding agent 16, thermally treating the bonding agent, and then applying over the bonding agent one or more coats of a ceramic material which are fired. The metal core is a nickel-chromium alloy also containing carbon, manganese, iron and boron, and the keying depressions are formed by a slotted milling cutter mounted on a turbine. The surface of the metal is degreased by immersing the core in a bath of hydrofluoric acid, and the core is degassed by firing it in a kiln at 700‹C. The bonding agent consists of a suspension of an oxidising agent such as white tin oxide or potassium oxide in a liquid, and the thermal treatment of the bonding agent comprises heating it in a kiln from 700‹C to 1050‹C in vacuo. A ceramic coating 18 is applied to the surface of the bonding agent by sprinkling ceramic material on to the surface and firing, preferably in vacuo in a conventional manner. Further ceramic coats are then similarly applied, the total number of coats not exceeding five. The layers of bonding material and ceramic material are supported on a shoulder 12 on either the metal core or the dental preparation in which the core is inserted.
The present invention provides methods for identifying compounds that can induce cellular chemokinesis. According to the present invention, chemokinesis interferes with immune and inflammatory responses by increasing cell movements and altering cell migration patterns. Surprisingly, compounds isolated according to the present invention can interfere with the spread of malignant cells through the body, reduce inflammatory responses and can cause leukocytes to be retained in lymph nodes, the spleen and other organs of the reticulo-endothelial system. Several methods are contemplated by the present invention for identifying compounds which can induce chemokinesis. In one embodiment the method involves contacting a population of target cells with a test compound and observing whether the target cells produce a chemotactic molecule; wherein the target cell has a cognate receptor for the chemotactic molecule. In another embodiment, the method involves contacting a population of target cells with a test compound and observing whether the targets cells homotypically aggregate. In yet another embodiment, the method involves contacting a population of target cells with a test compound and observing whether actin filaments in the target cells form stress fibers.
PURPOSE:To enable easy identification and classification of the Aspergillus germ in the sputum and tissue by using a reagent contg. the antibody secreted from the hybridoma of antiaspergillus antibody producing cells and the cells which can be subcultured in vitro (in test tube) for a long period of time. CONSTITUTION:Aspergillus fumigatus is cultured and a mouse immunized with the spore of said germ as an immunogen, by which the hybridoma between the pulpar cells thereof and the myeloma cells of the previously cultured mouse is obtd. The stable clone having high antibody secretory power and excellent proliferation in said hybridoma is selected and the antibody producing hybridoma (syncytium) is obtd. A reagent contg. the antibody secreted by said hybridoma or a deriv. of the antibody marked with enzyme, radioactive material, fluorescent dye, etc. or the restriction-decomposed matter of the antibody, for example, F(ab')2 is obtd. The activity in marking or the like of the conjugate generated by the reaction between such reagent and the patient's sputum are measured, by which the identification and classification are accomplished with good accuracy.
Individuals receiving asynchronous exercise content and are not responding. The are receiving 1 on 1 live exercise sessions.
Participants will perform sensorimotor training intervention. Nerve stimulation will be applied to the second through fifth digits and the wrist of the affected limb to cue movement. This intervention will be performed approximately 4 days per week for 4 weeks. In addition, participants will experience their standard medical care.
Participants assigned to this arm will engage in the storytelling component of the ARTISAN Intervention framework. Youths and senior participants in this condition will be paired to engage in a 5-weekly, 5-hour, group-based guided storytelling activity that covers the five ARTISAN themes.